$58.18
2.94% today
Nasdaq, Nov 06, 10:00 pm CET

Bio-Techne Corporation Target price 2025 - Analyst rating & recommendation

Bio-Techne Corporation Classifications & Recommendation:

Buy
78%
Hold
22%

Bio-Techne Corporation Price Target

Target Price $67.32
Price $59.94
Potential
Number of Estimates 16
16 Analysts have issued a price target Bio-Techne Corporation 2026 . The average Bio-Techne Corporation target price is $67.32. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 23 analysts: 18 Analysts recommend Bio-Techne Corporation to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bio-Techne Corporation stock has an average upside potential 2026 of . Most analysts recommend the Bio-Techne Corporation stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '25 2026
Estimates
Revenue Billion $ 1.22 1.27
5.23% 3.97%
EBITDA Margin 24.32% 35.54%
0.86% 46.11%
Net Margin 6.01% 25.00%
58.52% 315.64%

18 Analysts have issued a sales forecast Bio-Techne Corporation 2026 . The average Bio-Techne Corporation sales estimate is

$1.3b
Unlock
. This is
3.97% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.3b 8.15%
Unlock
, the lowest is
$1.2b 1.36%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $1.2b 5.23%
2026
$1.3b 3.97%
Unlock
2027
$1.4b 7.81%
Unlock
2028
$1.5b 10.02%
Unlock
2029
$1.6b 5.25%
Unlock
2030
$1.8b 10.55%
Unlock

17 Analysts have issued an Bio-Techne Corporation EBITDA forecast 2026. The average Bio-Techne Corporation EBITDA estimate is

$451m
Unlock
. This is
20.18% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$494m 31.73%
Unlock
, the lowest is
$420m 11.88%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $297m 4.33%
2026
$451m 51.90%
Unlock
2027
$500m 10.94%
Unlock
2028
$567m 13.44%
Unlock
2029
$574m 1.22%
Unlock
2030
$580m 1.00%
Unlock

EBITDA Margin

2025 24.32% 0.86%
2026
35.54% 46.11%
Unlock
2027
36.57% 2.90%
Unlock
2028
37.71% 3.12%
Unlock
2029
36.26% 3.85%
Unlock
2030
33.13% 8.63%
Unlock

19 Bio-Techne Corporation Analysts have issued a net profit forecast 2026. The average Bio-Techne Corporation net profit estimate is

$317m
Unlock
. This is
338.72% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$337m 366.14%
Unlock
, the lowest is
$287m 297.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $73.4m 56.35%
2026
$317m 332.14%
Unlock
2027
$355m 11.93%
Unlock
2028
$413m 16.42%
Unlock
2029
$435m 5.22%
Unlock
2030
$452m 4.00%
Unlock

Net Margin

2025 6.01% 58.52%
2026
25.00% 315.64%
Unlock
2027
25.96% 3.84%
Unlock
2028
27.47% 5.82%
Unlock
2029
27.46% 0.04%
Unlock
2030
25.83% 5.94%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '25 2026
Estimates
Earnings Per Share $ 0.46 2.05
56.19% 345.65%
P/E 29.30
EV/Sales 7.50

19 Analysts have issued a Bio-Techne Corporation forecast for earnings per share. The average Bio-Techne Corporation EPS is

$2.05
Unlock
. This is
355.56% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$2.17 382.22%
Unlock
, the lowest is
$1.85 311.11%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $0.46 56.19%
2026
$2.05 345.65%
Unlock
2027
$2.29 11.71%
Unlock
2028
$2.67 16.59%
Unlock
2029
$2.81 5.24%
Unlock
2030
$2.92 3.91%
Unlock

P/E ratio

Current 133.20 122.86%
2026
29.30 78.00%
Unlock
2027
26.18 10.65%
Unlock
2028
22.48 14.13%
Unlock
2029
21.37 4.94%
Unlock
2030
20.55 3.84%
Unlock

Based on analysts' sales estimates for 2026, the Bio-Techne Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.80 6.47%
2026
7.50 3.78%
Unlock
2027
6.96 7.24%
Unlock
2028
6.33 9.11%
Unlock
2029
6.01 4.99%
Unlock
2030
5.44 9.54%
Unlock

P/S ratio

Current 7.65 7.37%
2026
7.36 3.81%
Unlock
2027
6.83 7.24%
Unlock
2028
6.21 9.11%
Unlock
2029
5.90 4.99%
Unlock
2030
5.33 9.54%
Unlock

Current Bio-Techne Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
TD Cowen
Locked
Locked
Locked Oct 14 2025
Evercore ISI Group
Locked
Locked
Locked Oct 07 2025
RBC Capital
Locked
Locked
Locked Sep 03 2025
Citigroup
Locked
Locked
Locked Aug 21 2025
RBC Capital
Locked
Locked
Locked Aug 07 2025
Scotiabank
Locked
Locked
Locked Jul 11 2025
TD Cowen
Locked
Locked
Locked Jul 09 2025
Analyst Rating Date
Locked
TD Cowen:
Locked
Locked
Oct 14 2025
Locked
Evercore ISI Group:
Locked
Locked
Oct 07 2025
Locked
RBC Capital:
Locked
Locked
Sep 03 2025
Locked
Citigroup:
Locked
Locked
Aug 21 2025
Locked
RBC Capital:
Locked
Locked
Aug 07 2025
Locked
Scotiabank:
Locked
Locked
Jul 11 2025
Locked
TD Cowen:
Locked
Locked
Jul 09 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today